Conditioned only upon the prior consummation and implementation of the Scheme and the Acquisition, an indirect subsidiary of New Perrigo (“Merger Sub”), will merge with and into Perrigo, as a result of which the separate corporate existence of Merger Sub will cease and Perrigo will continue as the surviving corporation as a wholly owned indirect subsidiary of New Perrigo. At the Effective Date, all Perrigo shares will be cancelled and each Perrigo share will automatically be converted into the right to receive one New Perrigo share and US$0.01 in cash.

For more information:  

Elan Investor Relations:
Chris Burns +1-800-252-3526
David Marshall +353-1-709-4444
Elan Media Relations:
Emer Reynolds +353-1-709-4022
Financial Advisors to Elan:
Chris Hite +1-212-816-1818
Eugenée Mulhern +353-1-679-6363
Morgan Stanley
Colm Donlon +44-20-7425-8000
Michael Tory +44-20-7082-8750
PR Advisors to Elan:
Sutton Belmont
Jonathan Birt +44-78-6036-1746
FTI Consulting
Susan Stuart +44-20-7269-7169
Sard Verbinnen & Co
Jamie Tully +1-212-687-8080

Perrigo Investor Relations

Arthur Shannon

Bradley Joseph +1-269-686-3373
Financial Advisor to Perrigo:
Punit Mehta +1-212-526-7000
Derek Shakespeare +44-20-7773-2500
PR Advisors to Perrigo:
FTI Consulting
Mark McCall +1-212-850-5641
David Roady +1-212-850-5632

The Perrigo directors accept responsibility for all the information contained in this announcement other than information relating to Elan and its subsidiary undertakings, the directors of Elan and members of their immediate families, related trusts and persons connected with them. To the best of the knowledge and belief of the Perrigo directors (who have taken all reasonable care to ensure that such is the case), the information in this announcement for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information.

If you liked this article you might like

McDonald's Takes Bite Out of Dow, but Nasdaq and S&P 500 at Records

Perrigo Stock Jumps as Starboard's Smith Says Generic Drugs a Strong Business

Valeant CEO Confident Divestitures Can Successfully Pare Debt, Skeptics Remain

These Stocks Have Changed Direction

Stocks Tank as Trump, North Korea Exchange Barbs